Patents Assigned to THERAWIS DIAGNOSTICS GMBH
  • METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION
    Publication number: 20190323084
    Abstract: The present invention relates to methods for predicting the efficacy of anthracycline-based neo-adjuvant chemotherapy in triple-negative breast cancer. This is achieved by determining epigenetic changes within the PITX2 gene. Detection of the methylation state of Cp G sites in a genomic sequence of PITX2 allows an estimate of the response or failure of an individual breast cancer patient to neo-adjuvant therapy.
    Type: Application
    Filed: February 10, 2017
    Publication date: October 24, 2019
    Applicant: THERAWIS DIAGNOSTICS GMBH
    Inventors: Manfred SCHMITT, Olaf G. WILHELM, Rudolf NAPIERALSKI
  • Markers for the prediction of outcome of anthracycline treatment
    Patent number: 10053735
    Abstract: The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: August 21, 2018
    Assignee: THERAWIS DIAGNOSTICS GMBH
    Inventors: John Foekens, John W. Martens, Serenella Eppenberger-Castori, Vincent Vuaroqueaux, Frederique Spyratos, Nadia Harbeck, Manfred Schmitt, Heinz Hoefler, Sabine Maier, Gunter Weiss, Ralf Lesche, Thomas Hildmann, Achim Plum